Abstract P230 – Table 1. Rate of potential drug‐drug interaction or contraindication with each first‐line recommended ART regimen per patient per year

Regimens	Overall population (n = 2680)
Dolutegravir/abacavir/lamivudine	0.159
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	0.851
Bictegravir/emtricitabine/tenofovir alafenamide	0.218
Dolutegravir+emtricitabine/tenofovir alafenamide	0.174
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide	1.014
Raltegravir+emtricitabine/tenofovir alafenamide	0.150
Rilpivirine/emtricitabine/tenofovir alafenamide	0.422